FDA oks Novartis, Roche treatment for hives


The FDA has approved Novartis' (NVS) and Roche's (RHHBY) Xolair treatment for Chronic Idiopathic Urticaria (CIU), a form of hives.

Xolair is the first biologic medicine to be approved for CIU, a skin condition that can cause severe itching and can last for many years. Around 1.5M people in the U.S. develop CIU at some point in their lives.

"Nearly 50% of patients have inadequate response to H1-antihistamines, previously the only approved therapy for CIU," Roche says.

The FDA's authorization covers people 12 years old and older who still suffer symptoms of CIU despite treatment with H1-antihistamines.

Xolair is also approved for moderate-to-severe persistent allergic asthma. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs